MSL
BBIO icon

Mackay Shields LLC’s BridgeBio Pharma BBIO Stock Holding History

Mackay Shields LLC’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,300
Closed -$1.74M – 772
2021
Q1 		$1.74M Sell
28,300
-16,600
-37% -$1.09M 0.01% 825
2020
Q4 		$3.19M Sell
44,900
-8,200
-15% -$396K 0.02% 642
2020
Q3 		$1.99M Buy
53,100
+400
+0.8% +$12.6K 0.01% 790
2020
Q2 		$1.72M Buy
+52,700
New +$1.61M 0.01% 828

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Mackay Shields LLC's BBIO Position: Q2 2021 in Review

Mackay Shields LLC sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 28,300 shares — an estimated $1.74M sold.

Mackay Shields LLC first reported a position in BBIO in Q2 2020 and held it in 4 quarters. The position peaked at $3.19M in Q4 2020. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

  • Mackay Shields LLC reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 28,300 BridgeBio Pharma shares in Q2 2021, an estimated $1.74M.
  • Mackay Shields LLC first reported a position in BridgeBio Pharma in Q2 2020 and held it in 4 quarters.
  • Mackay Shields LLC's BridgeBio Pharma position peaked at $3.19M in Q4 2020.
  • 200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.